Revolutionizing Food And Drug Production Through R&D And Biotech

We use our patented biosynthesis process to design, develop and manufacture next-generation compounds - changing the game in Pharma, Nutraceuticals, Cosmetics, Food, Psychedelics, and more.

Invest with us and play your part in the sustainable, scalable biotech revolution

Register Your Interest For Our Crowdfunding Launch
on Republic >>> 

Highlights

  • Raised Series A round of $5M. Total raised to date: $11.5M 
  • Notable investors include reMind Capital, Christian Angermayer, VCs including Metaplanet Holdings, Third Kind Venture Capital, Fort Ventures, Capital Energy Corp, Pioneer Fund
  • Generating revenue in partnership with atai Life Science, the world’s leading listed psychedelics company
  • Profitable by end of 2022 - generating c.$250K per month in recurring revenue with more clients joining all the time
  • Medical Advisory Board consisting of Dr. Stephen Wright (ex-Chief Medical Officer for GW Pharma, which sold to Jazz Pharma for $8B), Dr. Brian Barnett, Assistant Professor at the Cleveland Clinic
  • The first company to develop and get granted a patent on the biosynthetic production of psilocybin and other active molecules in magic mushrooms.

Highlights

  • Raised Series A round of $5M. Total raised to date: $11.5M 
  • Notable investors include reMind Capital, Christian Angermayer, VCs including Metaplanet Holdings, Third Kind Venture Capital, Fort Ventures, Capital Energy Corp, Pioneer Fund
  • Generating revenue in partnership with atai Life Science, the world’s leading listed psychedelics company
  • Profitable by end of 2022 - generating c.$250K per month in recurring revenue with more clients joining all the time
  • Medical Advisory Board consisting of Dr. Stephen Wright (ex-Chief Medical Officer for GW Pharma, which sold to Jazz Pharma for $8B), Dr. Brian Barnett, Assistant Professor at the Cleveland Clinic
  • The first company to develop and get granted a patent on the biosynthetic production of psilocybin and other active molecules in magic mushrooms.

Why Are We Special?

We create sustainable, innovative bio-manufacturing solutions to supply a wide range of industries - from clinical research and nutraceuticals to cosmetics and the food and beverage markets. 

Established in 2015, our biotech platform can produce any food or pharmaceutical product using fewer resources, with more efficiency, at a cheaper cost. Our production methods are also better for the environment.

Our steady growth has also allowed us to:

  • Achieve 7 granted patents on our technology
  • File an additional 13 patents on new innovations
  • Expand our platform to be able to produce ANY natural molecule at a fraction of the cost and time it takes other biotech companies to do the same
  • Relocate to a 16,000-square-foot custom-built facility to expand our research labs. Our new facility allows us to streamline development, be more cost-effective and attract more customers

Why Are We Special?

Our industry is growing at an incredible rate. It’s currently worth $40B per year, but let’s look to the future:

Precision Fermentation:

will grow to

$36B

by 2030

Food tech:

$342B

by 2027

Psychedelics:

$11B

by 2029

Cannabinoids:

$54B

by 2029

We are profitable by end of 2022.

How many 7-year-old biotech companies can say that?

Excellent team with a track record of biotechnology success

Our IP portfolio puts up steep barriers to entry for would-be competitors

Our products are recession-proof:

  • Cannabinoids and psychedelics are used for mental health and wellness. In tough economic times, their use goes up
  • The world is crying out for cheaper food prod

World challenges like climate change, environmental damage, supply chain issues and a mental health crisis make the need for companies like ours stronger than ever. As we grow, expect a looser regulatory environment.

About Us

Sher Butt

CEO / Founder

Sher holds a BSc in Biochemistry & Molecular Biology from UC Davis and an MBA from the Rady School of Management, UC San Diego.

Jacob Vogan

CSO / Founder

Jacob has over 16 years of experience in bioengineering and has authored more than two dozen scientific articles and patents. Jacob completed his PhD and Post-Doc at UC Berkeley, with additional research experience at UC Davis and UC San Francisco.

Thanos Karavokiris

Vice President, Operations

As Vice President of Operations, Thanos oversees all of CB Therapeutics’ non-scientific operations. His experience spans over 25 successful years of helping companies (including Fortune 500 giants) through their mergers, acquisitions, and initial public offerings.

Register Your Interest For Our Crowdfunding Launch on Republic